Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703297 · ClinicalTrials.gov registry record · Phase 3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
A Phase 3 study of Small-cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT03703297 is a Phase 3 study of Small-cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 730 participants, above the 223-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT03703297, a Phase 3 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Orange City
- Research Site - St. Petersburg
Maryland
- Research Site - Annapolis
- Research Site - Baltimore
- Research Site - Towson
Indiana
- Research Site - Fort Wayne
- Research Site - Muncie
Michigan
- Research Site - Detroit
- Research Site - Grand Rapids
Arizona
- Research Site - Tucson
California
- Research Site - Santa Rosa
Connecticut
- Research Site - New Haven
Georgia
- Research Site - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2026-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703297
The ClinicalTrials.gov registry entry for NCT03703297 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 223-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (227% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03703297 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Maryland, Indiana.
Frequently Asked Questions
What is clinical trial NCT03703297 about?
NCT03703297 is a clinical study titled "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy". This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
What is the current status of trial NCT03703297?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2018-09-27. Estimated completion is 2026-10-23.
What conditions does trial NCT03703297 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03703297?
The interventions under investigation include: Placebo (OTHER), Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03703297?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03703297 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.